Skip to main content

Table 5 Antineoplastic treatment effect on BMD and BMC depending on menopausal status and clinical stage in breast cancer patients (n = 40)

From: Antineoplastic treatment effect on bone mineral density in Mexican breast cancer patients

Parameter

Premenopause (n = 19)

Postmenopause (n = 21)

βa

p

Confidence Interval

95 %

βa

p

Confidence Interval

95 %

BMD femoral neck (g/cm2)b

All

−0.023

<0.001

(−0.032, −0.013)

−0.015

0.021

(−0.027, −0.002)

 Clinical stage I, IIA (n = 17)c

−0.030

0.004

(−0.047, −0.013)

−0.018

0.037

(−0.034, −0.001)

 Clinical stage IIB, IIIA, IIIB (n = 23)c

−0.017

0.007

(−0.029, −0.006)

−0.0123

0.198

(−0.032, 0.008)

BMD L2-L4 (g/cm2)b

All

−0.063

<0.001

(−0.086, −0.039)

−0.035

0.001

(−0.054, −0.016)

 Clinical stage I, IIA (n = 17)c

−0.059

0.006

(−0.095, −0.023)

−0.043

<0.001

(−0.059, −0.026)

 Clinical stage IIB, IIIA, IIIB (n = 23)c

−0.066

0.003

(−0.102, −0.029)

−0.029

0.088

(−0.062, 0.005)

BMC (kg)b

All

−0.027

0.29

(−0.078, 0.025)

−0.036

0.140

(−0.085, 0.013)

 Clinical stage I, IIA (n = 17)c

−0.019

0.66

(−0.118, 0.079)

−0.005

0.895

(−0.088, 0.078)

 Clinical stage IIB, IIIA, IIIB (n = 23)c

−0.032

0.33

(−0.103, 0.038)

−0.059

0.078

(−0.126, 0.008)

  1. BMD Bone Mineral Density, BMC Bone Mineral Content
  2. aDetermined by mixed model regression for repeated measures
  3. bMenopausal status and treatment interaction (p ≤ 0.05)
  4. cMenopausal status and clinical stage interaction (p ≤ 0.05)